Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin

Liu, Anchang; Lou, Hongxiang; Zhao, Lei; Fan, Peihong

doi:10.1016/j.jpba.2005.09.032

Cited by 233 publications

(144 citation statements)

References 8 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Thus, poor bioavailability is the major weak point of curcumin and has been the main challenge for physicians seeking to verify the therapeutic efficacy of this promising agent in clinical trials. Therefore, many efforts have been made to improve its bioavailability through several approaches including innovative drug delivery systems (liposomes, nanoparticles and phospholipids) (Anand et al, 2010;Antony et al, 2008;Bisht et al, 2007;Das et al, 2010;Gupta et al, 2009;Koppolu et al, 2010;Li et al, 2005;Liu et al, 2006;Marczylo et al, 2007;Mukerjee & Vishwanatha, 2009;Sahu et al, 2008;Shaikh et al, 2009;Sou et al, 2008;Takahashi et al, 2009), or the development of new curcumin analogues Mosley et al, 2007;Ohori et al, 2006;Sato et al, 2011). A nanoparticlebased drug delivery system is effective in improving the water solubility of hydrophobic agents like curcumin, and the development of at least 8 different types of nanoparticlebased curcumin have been published up to this point (Anand et al, 2010;Bisht et al, 2007; Das et al, 2010;Gupta et al, 2009;Mukerjee & Vishwanatha, 2009;Shaikh et al, 2009;Sou et al, 2008).…”

Section: Development Of a New Form Of Curcumin With Improved Bioavailmentioning

confidence: 99%

The Potential Role of Curcumin for Treatment of Pancreatic Cancer

Kanai¹,

Guha²,

Aggarwal³

2012

Pancreatic Cancer - Molecular Mechanism and Targets

View full text Add to dashboard Cite

Section: Development Of a New Form Of Curcumin With Improved Bioavailmentioning

confidence: 99%

The Potential Role of Curcumin for Treatment of Pancreatic Cancer

Kanai¹,

Guha²,

Aggarwal³

2012

Pancreatic Cancer - Molecular Mechanism and Targets

View full text Add to dashboard Cite

“…Particularly, X 2 was found to exhibit significant influence on complexation rate (in percent). Both non-polar solvent and polar solvent can be used to prepare phytosome (vegetal phospholipid complex) (10,16,19,(21)(22)(23)(24). On one hand, our preliminary study showed that the complexation rate of EPLC prepared by non-polar solvent (e.g., tetrahydrofuran) was usually much higher than that prepared by polar solvent (e.g., ethanol) when the same amount of EVO was added.…”

mentioning

confidence: 99%

Design and Evaluation of a Novel Evodiamine-Phospholipid Complex for Improved Oral Bioavailability

et al. 2012

View full text Add to dashboard Cite

Abstract. A novel evodiamine (EVO)-phospholipid complex (EPLC) was designed to improve the bioavailability of EVO. A central composite design approach was employed for process optimization. EPLC were characterized by differential scanning calorimetry, ultraviolet spectroscopy, Fourier transformed infrared spectroscopy, 1 H-NMR spectroscopy, matrix-assisted laser desorption/ionization time-offlight spectroscopy, apparent solubility, and dissolution rate. After oral administration of EPLC, the concentrations of EVO at different time points were determined by high-performance liquid chromatography. The optimal formulation for EPLC was obtained where the values of X 1 , X 2 , and X 3 were 2, 0.5, and 2.5 mg/mL, respectively. The average particle size and zeta potential of EPLC with the optimized formulation were 246.1 nm and −26.94 mV, respectively. The EVO and phospholipids in the EPLC were associated with non-covalent interactions. The solubility of EPLC in water and the dissolution rate of EPLC in phosphate-buffered solution (pH 6.8) were substantially enhanced. The plasma EVO concentration-time curves of EPLC and free EVO were both in accordance with the two-compartment model. The peak concentration and AUC 0−∞ of EPLC were increased, and the relative bioavailability was significantly increased to 218.82 % compared with that of EVO.

show abstract

“…46,47 Additionally, complexing curcumin with micelles or phospholipids has proved to improve its bioavailability. 48,49 Finally, synthetic curcumin analogs (e.g. EF-24, HO-3867) were reported to have increased bioavailability when compared to curcumin and are more effective than curcumin at suppressing tumor growth.…”

Section: Discussionmentioning

confidence: 99%